mitomycin has been researched along with Blood Loss, Surgical in 4 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
Blood Loss, Surgical: Loss of blood during a surgical procedure.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oxaliplatin and Mitomycin C (MMC) are both suitable as intraperitoneal chemotherapy agents in HIPEC for peritoneal carcinomatosis (PC) of colorectal cancer (CRC)." | 7.80 | The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. ( Bruin, S; D'Hoore, A; Fieuws, S; Hompes, D; Mirck, B; Verwaal, V; Wolthuis, A, 2014) |
| "Oxaliplatin and Mitomycin C (MMC) are both suitable as intraperitoneal chemotherapy agents in HIPEC for peritoneal carcinomatosis (PC) of colorectal cancer (CRC)." | 3.80 | The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study. ( Bruin, S; D'Hoore, A; Fieuws, S; Hompes, D; Mirck, B; Verwaal, V; Wolthuis, A, 2014) |
| "In order to determine whether preresectional chemoradiotherapy (CTRT) would influence resectability, local control, and survival of patients with localized pancreatic adenocarcinoma, a 5 1/2-year prospective study of 39 patients treated with preoperative radiation therapy, 5-Fluorouracil (5-FU), and Mitomycin C has been performed." | 3.68 | A single institutional experience with preoperative chemoradiotherapy for stage I-III pancreatic adenocarcinoma. ( Agarwal, P; Eisenberg, BL; Engstrom, P; Hoffman, JP; Litwin, S; Paul, AR; Scher, R; Solin, LJ; Watts, P; Weese, JL, 1993) |
| " The study is to analyze the incidence of perioperative serious adverse events (SAEs) of CRS + HIPEC to treat PMP patients, and identify the risk factors, for guiding the prevention of SAEs." | 1.56 | Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center. ( Chen, LF; Ji, ZH; Li, XB; Li, Y; Lin, YL; Ma, R; Yan, FC; Yang, ZR; Zhang, J, 2020) |
| "In patients undergoing colorectal cancer surgery, skeletal muscle depletion (sarcopenia) is associated with impaired postoperative recovery and decreased survival." | 1.42 | Skeletal Muscle Depletion is Associated with Severe Postoperative Complications in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Cancer. ( Boerma, D; Bollen, TL; Braam, HJ; de Hingh, IH; van Oudheusden, TR; van Ramshorst, B; van Vugt, JL; Vestering, A; Wiezer, MJ, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, XB | 1 |
| Ma, R | 1 |
| Ji, ZH | 1 |
| Lin, YL | 1 |
| Zhang, J | 1 |
| Yang, ZR | 1 |
| Chen, LF | 1 |
| Yan, FC | 1 |
| Li, Y | 1 |
| Hompes, D | 1 |
| D'Hoore, A | 1 |
| Wolthuis, A | 1 |
| Fieuws, S | 1 |
| Mirck, B | 1 |
| Bruin, S | 1 |
| Verwaal, V | 1 |
| van Vugt, JL | 1 |
| Braam, HJ | 1 |
| van Oudheusden, TR | 1 |
| Vestering, A | 1 |
| Bollen, TL | 1 |
| Wiezer, MJ | 1 |
| de Hingh, IH | 1 |
| van Ramshorst, B | 1 |
| Boerma, D | 1 |
| Hoffman, JP | 1 |
| Weese, JL | 1 |
| Solin, LJ | 1 |
| Agarwal, P | 1 |
| Engstrom, P | 1 |
| Scher, R | 1 |
| Paul, AR | 1 |
| Litwin, S | 1 |
| Watts, P | 1 |
| Eisenberg, BL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superio[NCT02758951] | Phase 2/Phase 3 | 358 participants (Anticipated) | Interventional | 2017-06-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for mitomycin and Blood Loss, Surgical
| Article | Year |
|---|---|
Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasm | 2020 |
The use of Oxaliplatin or Mitomycin C in HIPEC treatment for peritoneal carcinomatosis from colorectal cancer: a comparative study.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Blood Loss, Surgical; Chemotherapy, Ca | 2014 |
Skeletal Muscle Depletion is Associated with Severe Postoperative Complications in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Cancer.
Topics: Aged; Antineoplastic Agents; Blood Loss, Surgical; Colorectal Neoplasms; Cytoreduction Surgical Proc | 2015 |
A single institutional experience with preoperative chemoradiotherapy for stage I-III pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgi | 1993 |